How penicillin allergy labels can be reviewed across care settings

This guide helps allergy and immunology practices, primary care teams and pharmacists coordinate reviews of penicillin allergy labels. It lays out steps for gathering a useful history, routing patients by risk, choosing an evaluation pathway and carrying results into the records other care teams use.

Start with a clear history

Begin by finding out what the penicillin allergy label describes. The CDC says clinicians can review a patient's allergy history and use validated risk stratification, followed by skin testing and/or direct oral challenge as appropriate. That sequence gives teams a shared starting point whether the label appears in primary care, a hospital chart, a pharmacy record or an allergy referral.

A structured interview can make the history easier to assess. In a report about pharmacy students trained by an infectious diseases pharmacist, the students used a questionnaire interview for penicillin allergy reconciliation and were effective at identifying improper labels. A practice can define who gathers this information and how it reaches the clinician responsible for assessment and the record decision.

Use history to route the next step

The CDC says patient history can establish penicillin allergy risk categories, and validated tools can estimate the risk of a positive test to guide clinical decisions. That gives a service a consistent way to sort histories before deciding whether a local clinician can continue the evaluation or whether allergy expertise is appropriate.

Authors writing about equitable access say symptoms not consistent with allergy, such as gastrointestinal symptoms, headache or fatigue, should prompt delabeling by clinicians without allergist referral. They say a high-risk history such as anaphylaxis can lead to referral to an allergist for validated penicillin testing. Allergist Kimberly Blumenthal has also described distinguishing a low-risk reaction history from a high-risk host. In her example, a patient using oxygen while awaiting lung transplant had a low-risk reaction history, but she chose skin testing because she considered the patient a high-risk human. Blumenthal says allergists must identify people with systemic or severe delayed reactions.

Clinicians may differ on which test to use for a low-risk history. Allergist David Khan said he would generally not skin test low-risk patients because, in his view, false positive skin tests can impede delabeling. These perspectives support making the route explicit in a service protocol and applying it to the assessed history and clinical context.

Choose an evaluation pathway

The CDC's approach allows skin testing and/or direct oral challenge after history review and risk stratification. In a trial discussed by allergist Ana-Maria Copaescu, physician-verified immune-mediated reactions to oral penicillin challenge occurred in one case in each arm, and direct oral challenge was non-inferior to the standard of care used in that trial.

Khan's discussion of a study reported that direct challenge and skin testing followed by challenge were statistically the same, with a trend toward more effective delabeling for direct challenge. He said direct challenge was faster and less expensive. These findings can help a service compare pathways while using the risk assessment to guide the patient-specific choice.

Skin testing followed by an oral challenge is another pathway. Allergy & Asthma Network describes skin prick tests using gradually increasing amounts of penicillin, followed by an oral challenge if the tests are negative. The network says the oral challenge confirms a negative skin test and can ease concern about taking penicillin. It says the challenge should take place in a doctor's office or hospital.

Share work across trained teams

A UK outpatient service report describes delabeling delivered by non-allergy health workers in response to a worldwide shortage of allergy specialists. Its authors cite earlier work in Hong Kong in which nurses safely delivered direct oral challenges to low-risk outpatients. The British Society for Allergy and Clinical Immunology has a guideline for UK clinicians without allergy or immunology training who want to develop a hospital delabeling service.

A comparison of pharmacists and allergists found that pharmacist evaluation and delabeling were comparably effective and safe among low-risk patients. Patients evaluated by pharmacists reported greater improvement in health-related quality of life. A UK integrated care board response said allergy services alone could not deliver delabeling for the affected population and described using risk algorithms with validated oral challenges or skin tests so non-allergist clinicians, including pharmacists and medics, can clear records when a patient is confirmed not to be allergic.

For practice owners, a workable division of labor names who gathers the history, who applies the pathway, who oversees testing and who communicates the result. A UK inpatient case study describes a protocol that allowed pharmacists to conduct direct oral challenges under infectious diseases physician oversight.

Plan the clinic flow and follow-up

A nurse-run, pharmacist-led outpatient clinic in the UK reported that 191 of 326 contacted patients, or 58.6%, were categorized as low risk. Of those 191, 22 were delabeled on history alone, 54 were awaiting a direct oral challenge appointment or declined to attend, and 115 attended for challenge. Of the 115 who attended, 110, or 95.7%, were delabeled. The clinic's figures show how contact, history review, appointment attendance and challenge results can be tracked as separate steps.

In the UK inpatient case study, patients were monitored for one hour after an oral challenge. If no adverse reaction occurred, staff removed the allergy label and updated the electronic prescribing and medicines administration system. The patient could then be switched to a penicillin-based antibiotic, with follow-up on day three for delayed reactions.

A concrete service action is to assign an owner to each step, including the record update and follow-up. For an individual patient's health decisions, the patient should talk with their own doctor.

Keep the result consistent across records

A completed evaluation needs to reach the records used by the next care team. Allergist Anca Sani said some patients still had a penicillin allergy label in medical and pharmacy records despite negative testing, and some remained hesitant to take penicillins if prescribed.

A qualitative study of patient acceptance in primary care found that trust depended on testing in a safe environment, helping patients understand the difference between allergic reactions and side effects, and keeping communication consistent across healthcare settings. Bland said the long-term benefit of trainee-led delabeling is not well studied and noted that labels can reappear when someone mistakenly adds them back.

A study of urban Boston primary care found that referral to allergists for penicillin allergy assessment was rare and differed by race. Its authors called for larger studies with an equity focus. Practices can review whether referrals are completed and whether the final result remains consistent across records.

This page is general education only. It is not medical advice. Talk with your own doctor about your health.

Immunologists.com is a business directory and education site. It does not give medical advice, rank or rate care, or refer patients. Listings come from public registry data and are not endorsements.